FilingReader Intelligence
Immunotech Biopharm loss jumps 39% on investment swing
August 20, 2025 at 05:01 PM UTC•By FilingReader AI
Immunotech Biopharm reported a loss before tax of RMB129m for the six months ended June 30, up 39.4% from RMB92.6m in 2024.
The increase was primarily due to a RMB51m net loss from other gains and losses, reversing a RMB19.8m gain in 2024. R&D expenses decreased 26% to RMB67.4m.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:6978•Hong Kong Exchange
News Alerts
Get instant email alerts when Immunotech Biopharm publishes news
Free account required • Unsubscribe anytime